CDX-1140, A Novel Agonist CD40 Antibody with Potent Anti-lymphoma Activity
Frontiers | Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer | Science Translational Medicine
![PDF] Agonistic CD40 Antibodies and Cancer Therapy | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/7cb235318895039cd45eb055391de568e99105c1/2-Table1-1.png "PDF] Agonistic CD40 Antibodies and Cancer Therapy | Semantic Scholar")
PDF] Agonistic CD40 Antibodies and Cancer Therapy | Semantic Scholar
CD40 therapy and surgery: a potential immunologic partnership. - Abstract - Europe PMC
Frontiers | CD40L and Its Receptors in Atherothrombosis—An Update
Anti-CD40 Antibody - Pipeline Insight, 2022
model of the potential effects of agonist anti-CD40 on the T-cell... | Download Scientific Diagram
List of clinically used agonistic CD40 antibodies | Download Scientific Diagram
Frontiers | Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
InVivoMAb anti-mouse CD40 | Bio X Cell
Cancers | Free Full-Text | Agonistic CD40 Antibodies in Cancer Treatment
CD40-agonist: A new avenue for immunotherapy combinations in cholangiocarcinoma - Journal of Hepatology
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study - The Lancet Oncology
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies | Cellular & Molecular Immunology
Line-selective macrophage activation with an anti-CD40 antibody drives a hemophagocytic syndrome in mice - ScienceDirect
CD40: Targeting Co-Stimulatory Pathways for Cancer Immunotherapy
Next-IO™ Anti-CD40 Therapeutic Monoclonal Antibody Program - Creative Biolabs
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint - ScienceDirect
Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment - Van Audenaerde - 2020 - Clinical & Translational Immunology - Wiley Online Library
Side effects of CD40 agonistic antibodies versus fusion molecules. | Download Scientific Diagram
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo- controlled, proof-of-concept study - The Lancet Rheumatology
IJMS | Free Full-Text | FcγRs and Their Relevance for the Activity of Anti-CD40 Antibodies
The Parker Institute for Cancer Immunotherapy and the Cancer Research Institute Announce First Patients Treated in Pancreatic Cancer Clinical Trial Combining Immunotherapy and Chemotherapy - Parker Institute for Cancer Immunotherapy
Anti-CD40 agonist antibodies may be the way to go for bladder cancer
